[A26-80] Teprotumumab (thyroid eye disease) – Addendum to Project A26-18
Last updated 20.08.2026
Project no.:
A26-80
Commission:
Commission awarded on 07.07.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Adults with moderate to severe thyroid eye disease
Result of dossier assessment:
- Patients in the acute disease phase receiving first-line treatment: unchanged after addendum: added benefit not proven
- Patients in the acute disease phase who are eligible for second-line treatment: unchanged after addendum: added benefit not proven
- Patients in the chronic disease phase: unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-80
| Project no. | Title | Status |
|---|---|---|
| A26-18 | Teprotumumab (thyroid eye disease) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
20-08-2026 A G-BA decision was published.
G-BA documents on this decision